How many insider trades does FilingIQ track for EDIT?

FilingIQ tracks 391 Form 4 insider transactions for EDIT (Editas Medicine, Inc.), covering filings from Feb 8, 2016 onwards. 5 of those are dated within the last 90 days.

Are EDIT insiders net buyers or net sellers?

Across the full Form 4 history for EDIT, 37 transactions (9%) were open-market purchases and 221 (57%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does EDIT insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is EDIT in?

Editas Medicine, Inc. (EDIT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $184.50M.

EDIT insider trading

NasdaqGS Healthcare

Editas Medicine, Inc.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

391

Last 90 days

Buys / sells

9% / 57%

Market cap

$184.50M

About Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Company website: www.editasmedicine.com

EDIT insider activity at a glance

FilingIQ tracks 391 insider transactions for EDIT in filings since Feb 8, 2016. The most recent transaction is dated Sep 3, 2026.

Across the full history, 37 open-market purchases and 221 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on EDIT insider trades is 47.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live EDIT trades on FilingIQ Raw filings on SEC EDGAR

Latest EDIT Form 4 filings

Ory Daniel Scott EVP, Chief Medical Officer

A Sep 9, 2026

Parison Amy SVP, Chief Financial Officer

S Sep 4, 2026

Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER

S Sep 4, 2026

O'Neill Gilmore Neil CEO

S Sep 4, 2026

Ellinor Patrick Thomas II

A Aug 7, 2026

Parison Amy SVP, Chief Financial Officer

S Aug 5, 2026

Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER

S Jul 29, 2026

Connaughton Bernadette

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 820

UNITED THERAPEUTICS Corp

THERMO FISHER SCIENTIFIC INC.

NTRA 129

Natera, Inc.

ATTO 123

Attovia Therapeutics, Inc.

CORT 110

CORCEPT THERAPEUTICS INC

TEM 104

Tempus AI, Inc.

Frequently asked

How many insider trades does FilingIQ track for EDIT?: FilingIQ tracks 391 Form 4 insider transactions for EDIT (Editas Medicine, Inc.), covering filings from Feb 8, 2016 onwards. 5 of those are dated within the last 90 days.
Are EDIT insiders net buyers or net sellers?: Across the full Form 4 history for EDIT, 37 transactions (9%) were open-market purchases and 221 (57%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does EDIT insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is EDIT in?: Editas Medicine, Inc. (EDIT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $184.50M.

Methodology & sources

Every EDIT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.